Nature Reviews Drug Discovery 8, 286-295 (April 2009) | doi:10.1038/nrd2826

OpinionA network view of disease and compound screening

Eric E. Schadt1, Stephen H. Friend2 & David A. Shaywitz3  About the authors


The large-scale generation and integration of genomic, proteomic, signalling and metabolomic data are increasingly allowing the construction of complex networks that provide a new framework for understanding the molecular basis of physiological or pathophysiological states. Network-based drug discovery aims to harness this knowledge to investigate and understand the impact of interventions, such as candidate drugs, on the molecular networks that define these states. In this article, we describe how such an approach offers a novel way to understand biology, characterize disease and ultimately develop improved therapies, and discuss the challenges to realizing these goals.

Author affiliations

  1. Eric E. Schadt is at Rosetta Inpharmatics, LLC, Merck & Co., Inc., 401 Terry Avenue North, Seattle, Washington 98109, USA.
  2. Stephen H. Friend is at Merck Research Laboratories, Merck & Co, Inc., Upper Gwynedd, Pennsylvania 19454, USA.
  3. David A. Shaywitz is at The Boston Consulting Group, 1 Prospect Street, Summit, New Jersey 07901, USA.

Correspondence to: Eric E. Schadt1 Email:

Correspondence to: David A. Shaywitz3 Email:


These links to content published by NPG are automatically generated.


Cause and express

Nature Biotechnology News and Views (01 Jun 2009)

From gene expression to disease risk

Nature Genetics News and Views (01 May 2008)

See all 4 matches for News And Views